Human Genetics Society), University of Utah Laboratory of Human Genetics, University of Texas, and University of Oklahoma. Johns Hopkins Medical Genetic Clinic began in 1957.
Since 1956, human genetics has become "medicalized, subspecialized, molecularized, commercialized, and consumerized" (McKusick, 1992) . While human genetics deals with biologic variation in the human, medical genetics deals with human biological variation as related to health and diseases. Medical genetics has become "professionalized" through the development of clinical colleges and certifying organizations. Clinical genetics becomes an integral part of medical genetics concerned with disorders not only in individual patients but also their families by diagnosis, prevention, and management of genetic disorders (McKusick, 1993) .
Genetic Services Providers
Most comprehensive genetics centers are located in large medical centers in urban settings and are often divisions within departments of pediatric, obstetric and gynecology, or medicine . Free standing departments of medical genetics such as ours are rare. Some centers or state genetics programs have established outreach clinics so that a larger segment of the population could have access to genetic services. Only the largest health maintenance organizations (e.g., Kaiser/Permanente in many locations) support their own genetics services. Private genetics services have been established in some areas and offer a limited number of services, such as cytogenetics, prenatal diagnostic procedures, or DNA analysis, or in a few instances, comprehensive services, including proband evaluation. Selected specialty hospitals that provide services for patients with certain types of disorders, such as orthopedic or carniofacial anomalies, may have a clinical geneticist or genetic counselor on staff.
Genetic services are usually provided by a multidisciplinary team of individuals with expertise in the diagnosis and management of genetic conditions as well as in information presentation and family support. In most clinical genetics centers, the core providers are clinical geneticists (physicians with subspecialty training in clinical genetics) and genetic counselors (professionals with graduate-degree level training in genetic counseling). Many multidisciplinary teams also include social workers and nurses who provide psychosocial support, crisis intervention, family follow-up, and referral to community resources (Alliance of Genetic Support Group, 1992).
Economic of Cinical Genetic Services
Genetic services in the United States became more widely available in the 1960's when the National Foundation-March of Dimes and other agencies began subsidizing the efforts of clinical centers in the treatment and prevention of birth defects (Myers and Prouty, 1987; Holtzman, 1983) . However, during the mid-1970's, the National Foundation weaned many previously supported genetic centers of major financial support. By that time, genetic services had already been widely recognized as "indicated" patient evaluations and patients and their insurance companies had assumed payments for these services. In 1976, the National Genetic Disease Act perpetuated and expanded the work of the National Foundation by subsidizing the efforts of ongoing genetic centers and assisting other genetic centers for possible funding. Three distinct areas of clinical services became chargeable: laboratory services, clinical diagnostic services (consultation), and genetic counseling.
In 1981, U.S. Congress, upon the urging of president Reagan, repealed laws that had authorized funding for categorical health and welfare programs, including genetic diseases and comprehensive hemophilia services. Simultaneously, congress passed Block Grants Acts that provided funds to the States for continuing these programs at their discretion. Maternal and Child Health (MCH) Service Block Grant Act included genetic services (and sickle cell programs) and hemophilia centers. The funds available in the set-aside Special Projects of Regional and National Significance (SPRANS) were considerably less than the funds allocated for the same programs in the previous years.
Clinical genetics is a relatively new speciality . Centers providing clinical genetic services have relied heavily on a variety of funding sources, especially federal, state, institutional, and foundation grants and subsidies from public and private sectors . However, during the past few years, most clinical genetics services have been supported increasingly by direct billings of patients (Bernhardt and Pyeritz, 1989) . Revision of Physician's Current Procedural Terminology (CPT) codes in 1987 had improved definition of genetic laboratory services but did not address the entire scope of cognitive genetic services. While not generating enough income to cover its own costs, clinical genetic services do bring considerable revenue to the medical center .
Increasingly, financial support of clinical services relies on income derived from direct patient charges. Fortunately, many genetics services have remained accessible because third party payers, including Medicaid, provide reimbursement for them. However, some new services, such as DNA diagnostic testing, or services that may be provided by non-physicians, such as genetic counseling, may not be reimbursed by all third parties.
Cognitive genetic services are by nature time consuming, labor intensive, and not self-supporting. Completing an evaluation of a new family referred for genetic diagnosis and counseling has been shown to require an average of 7 hours of staff time when considering the amount of time required before, during, and after the clinic appointment. In the United States, many states have recognized the importance of genetics services and partially subsidize genetics centers with state funding, allowing for provision of some free services, sliding fee scales for indigent families, and partial salaty support for providers. The extent to which economic factors affect genetic service accessibility and utilization and the effects on genetic services of future changes in health care regulations and financing has not been well studied.
Recent health care reform proposal by president Clinton focused on preventive medicine and availability of medical services to all citizens. Although direct consequences to genetic services in general will not be known for some time, it is felt that genetic services will continue to be supported.
Academic vs. Private
Commercial genetic-testing companies arose because they saw a market for their services and perceived a growth industry with the potential for considerable profits. In many instances, exclusive contracts have been negotiated between a third-party payor and a specific commercial laboratory, based primarily on fee structure, then on turnaround times, followed by delivery of services, but not so much to total cells analyzed or numbers of chromosome bands (Hecht and Hecht, 1992) . Potential problems for mega-commercial laboratories include (Milunsky, 1992a, b) : limitation of the knowledge on the subject matter by those private physicians who rely on the laboratory providing the test results; not directly involved in patient cares; rushing to market new techniques; and using master degree genetic counselors to practice medicine with liabilities to be shared by private physicians. Practicing physicians should be educated about importance of comprehensive genetic care for their patients, whether it be in the academic or the "private" setting.
American Board of Medical Genetics, American College of Medical Genetics, and Certification of Medical Geneticists
In 1990, the American Society of Human Genetics (ASHG) Board of Directors appointed a committee to evaluate the needs for and feasibility of establishing a College or Academy to oversee the provision of genetic services nationally, to represent the providers of these services and their patients with genetic disorders and to elevate the rapidly emerging specialty of Medical Genetics to full representation within the established medical service, certification and regulatory organizations. The committee recommended the establishment of the American College of Medical Genetics (ACMG), which was then incorporated as an independent body in December, 1991 (American College of Medical Genetics, 1991).
The American Board of Medical Genetics provides certification for five categories of genetics professionals and also sets standards for genetics training programs. Physicians are certified as specialists in Medical Genetics by the American Board of Medical Genetics, a member board of the American Board of Medical Specialties (ABMS). The establishment of the American Board of Medical Genetics evolved out of a recognized need and commitment by the founding members to improve the level and standards of clinical care in the area of medical genetics. To enforce its commitment to quality care at the individual level, the Board with the assistance of the National Board of Medical Examiners, instituted certifying examinations in these areas of expertise. These certifying examinations are offered every three years (i981, 1984, 1987, 1990, 1993, etc.) ( [1992] [1993] . Because the technology of medical genetics is advancing so rapidly, test questions must be thoroughly reviewed and rewritten each time to be sure that the geneticists who take the examinations are thoroughly up-to-date in a fast-moving field. In order to be eligible to sit for the examination, the candidate must have successfully completed at least a two year accredited training program and complete an application form with the appropriate documentation of didactic training and a logbook of cases.
Medical genetics programs have enjoyed steady development throughout U.S. for more than 20 years (Finley et al., 1987) . Current use of DNA probes will result in an even greater need for expansion of services. Therefore, organization of more training programs will be necessary to ensure that the needed personnel will be available and adequately trained. In order to ensure that state-of-the-art techniques, standards and practices are being met at the institutional level, a stringent process of accreditation has been made available to programs that train medical genetics professionals preparing for certification in the areas of clinical and laboratory medicine. In the U.S., there are 99 accredited graduate and postgraduate training programs in human genetics (American Society of Human Genetics, 1992). In addition, there are 11 cytogenetic technology training programs available (Knutsen, 1992) .
Since the Board's inception in 1979 and its incorporation in 1980, 994 M.D.'s and Ph.D's [957 from U.S.; 15 from Canada; 22 from foreign countries, including one from Japan (Dr. Jun Oizumi, a clinical geneticist at the National Children's Medical Research Center, Tokyo)] have become certified in the various specialty areas of medical genetics. Until 1991, the Board maintained itself as a separate and independent governing body with a philosophy of promoting equal importance to a variety of backgrounds in medical genetics. In December of 1991, the Board was approved for membership by the American Board of Medical Specialties with the provision that Master's level counselors would not be certified under the auspices of an ABMS approved board (Marquis Who's Who, 1994) .
Areas of certification include Clinical Geneticist, Ph.D. Medical Geneticist, Clinical Cytogeneticist, Clinical Biochemical Geneticist, and Clinical Molecular Geneticist. Subject areas of the general examination include 1) Basic Genetics, 2) Biochemical Genetics, 3) Clinical Genetics, 4) Cytogenetics, 5) Immunogenetics, 6) Mathematic genetics and risk assessment, and 7) Molecular Genetics.
Newborn Screening Tests Performed in U.S.A.
in Japan, newborn screening programs are primarily for early detection and treatment but genetic counseling and family services related to screenings are not adequate. However, in the United States, newborn screening programs are not only for early detection and treatment, but also an integral part of the comprehensive genetic services. Genetic counseling of families and prenatal diagnosis are one of the important purpose of newborn screening programs.
In most states, there are laws mandating newborn screening programs. The most classic one is the phenylketonuria (PKU) screening. Recently, the American Bar Foundation analyzed each state's laws and regulations governing newborn screening, compared alternatives taken in different states, and underscored the wide diversity of legislative and administrative oversight (Chen, 1988) . The screening tests, the number of states performing the test, and the incidence of the disease screened are given in the following table (Table 1) (Burist and Tuerck, 1992) :
Newborn Screenings in Ohio
In March 1962, Ohio participated in the national field trials of a bacterial inhibition assay developed by Dr. Robert Guthrie. The State Laboratory tested 28,901 infants from 19 hospitals and detected the first five cases of phenylketonuria (PKU) during this period. In June 1965 the Ohio General Assembly enacted the Revised State Code effective July 1966 to provide for mandatory testing of all infants born in Ohio. Homocystinuria, galactosemia, and hypothyroidism were added later. By 1990, a total of 4,022,285 newborns were screened which detected 297 PKU, 10 homocystinuria, 56 galactosemia, and 214 hypothyroidism (Chen, 1992) .
Hemoglobinopathies represent a major health problem in the United States and constitute the most common genetic disorder in some populations. Sickle cell anemia affects about 1 in 400 African-American newborns. In the State of Ohio, more than 2,800 residents are affected and at least 86,000 are carriers. In April 1987, the National Institutes of Health, Washington, D.C., conducted a consensus development conference which recommended early diagnosis including newborn screening and comprehensive care of hemoglobinopathies. In May 1989, the 10 regional networks and to encourage the development of minimum guidelines for services, laboratories, educational programs, collection of data, etc. In addition, CORN promotes the collection of data regarding genetic services in order to document the utilization of such services. The membership of CORN includes representatives from each of the 10 regional genetic services networks, the national sickle cell disease programs, the Alliance of Genetic Support Groups, genetic service providers, public health officials, consumers, and other health care professionals. Ohio belongs to Great Lakes Regional Genetics Group (GLaRGG) and Alabama to Southeast Regional Genetics Group (SERGG).
The operational activities of CORN are performed by standing committees which address the identified areas of concern in the discipline of genetics. At present, these committees are: Birth Defects Surveillance, Communications/Liaison, Data and Evaluation, Education, Ethics, Finance, Newborn Screening, Quality Assurance, Sickle Cell/Thalassemia and other Hemoglobin Variants, Teratogen Information Systems. The CORN committees are designed to study, plan, evaluate, report, recommend and implement projects and programs that are priorities of CORN.
For the past four years, the Data and Evaluation Committee of the CORN has surveyed genetic service centers throughout the United States to obtain information regarding the provision of prenatal, clinical, and laboratory genetic services. This collection effort is termed the CORN Minimum Data Set (MDS) collection and is supported by the U.S. Department of Health and Human Services Maternal and Child Health Bureau. The results of this survey are published in the annual CORN Minimum Data Set Report.
Cytogenetic Laboratory Services in the United States
328 public and private cytogenetic laboratories were listed in the International Cytogenetic Laboratory Directory by Association of Cytogenetic Technology (Knutsen, 1992) . 289 of those reported the numbers of procedures. The following table (Table 2) lists the number of procedures in the U.S.A. survey and compares them with that of Mobile Regional Genetic Services.
Clinical DNA Diagnostic Laboratory Services in the United States
According to CORN Survey of clinical DNA diagnostic laboratories (Corn Quality Assurance Committee DNA Testing Subcommittee, 1991), genetic disorders tested include: atpha-l-antitripsin deficiency, adenomatous polyposis coli, adult polycystic kidney disease, alpha-thalassemia, beta-thalassemia, congenital adrenal hyperplasia, cystic fibrosis, carbamylphosphate synthetase I deficiency, Duchenne/Becker muscular dystrophy, Ehlers-Danlos syndrome, familial amyloidosis, fragile X, Friedreich ataxia, Huntington disease, hemophilia A and B, Lesch Nyhan disease, myotonic dystrophy, multiple endocrine neoplasia type I and IIa, neurofibromatosis I, Norries disease, ornithine transcarbamylase deficiency, osteogenesis imperfecta, phenylketonuria, Pelizaeus-Merzbacher disease, PraderWilli syndrome, retinoblastoma, sickle cell disease, Tay-Sachs disease, WiskottAldrich disease, X-linked lymphoproliferative disease, and others. Non-genetic applications include: B cell rearrangements (heavy chain), DNA banking, Bcr rearrangements, bone marrow engraftment, forensic testing, x or X chian rearrangements (light chain), oncogenes, paternity testing, T cell markers and Y probes. Rapid progress in DNA testings during last few years have been reviewed by Cooper and Schmidtke (1993) .
Southeastern Regional Services (SERGG)
SERGG, one of the l0 regional genetic networks in U.S., is composed of genetic centers from 9 states: Alabama, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, and Tennessee [Southeastern Regional Group (SERGG), 1992] . Various Genetic Programs in this region are given in the following table (Table 3) .
Regional Genetic Services in South Alabama
[n 1973, the Medical Cotlege of the University of South Alabama accepted Jpn J Human Geuet its first class of medical students. Two years later, a free-standing Department of Medical Genetics was organized (Wertelecki, 1979 (Wertelecki, , 1991 . Alabama is a state of approximately one-third the size of Italy; its southern half, comprised of 31 counties, is the main focus of our educational programs. Our clinical and laboratory services, in addition to South Alabama, extend into the adjoining areas of Florida and Mississippi. Historically, the Gulf Coast was a cohesive part of the French and Spanish dominions and its development and character emerged from five settlements, now the coastal cities of Pensacola, Mobile, Pascagoula, Biloxi, and New Orleans. Pensacola was founded by the Spanish in 1696. Sixty miles west, in 1702, the French founded Mobile as the first capital of Louisiana, later moved to Biloxi in 1720 and to New Orleans in 1722. Subsequent incorporation have not altered a common legacy and de-facto demographic linkages. The Gulf Coast reflects noteworthy cultural and ethnic heterogeneity stemming from multiple waves of colonists and refugees, the latest from Vietnam and Cambodia.
The city of Mobile has a population of 365,000 and the Gulf Coast is relatively densely populated. Our services reach a coastal population of approximately 700,000 residing in three states. In addition, our services (university genetic clinics and six satellite clinics) and educational programs are focused on 31 South Alabama rural counties which represent approximately half of the State of Alabama (Wertelecki, 1991; Wertelecki et al., 1987) . Much of South Alabama is less developed than North Alabama or the Gulf Coast.
Our educational programs include training of medical students, house staff and fellows, practicing physicians, nurses, and teachers. Since 1976, a 40-hour course has been presented to each class of approximately 64 medical students at the end of their second year curriculum. The contact hours, when compared to other medical schools, are abundant and place us as the eighth highest in the country.
Programs for house staff and fellows rely primarily on clinical consultation and conferences. We also offer fellowships in clinical genetics and clinical cytogenetics and have provided training to ten fellows, five from abroad. Intensive clinical exercises (Mini-Residencies) are offered to practicing physicians by our staff and guest experts amalgamating advances in epidemiology, teratology, genetics and clinical medicine. Mini-Internships are provided to nurses and other health professionals by participating in a correspondence course and "hands-on" experience at our center. The last component of our educational programs is coordinated by a school teacher. Our goal is to reach teenagers, who will become future parents.
An "Information Center" was developed as a resource to provide timely and accurate information and materials to patients, families, teachers, health professionals and agencies. A computerized database (FAMFO) is used to facilitate the dissemination of information about national, regional and State support groups, fact sheets and books.
Significant effort and resources were invested to develop a series of computerized databases (Wertelecki and Superneau, 1978a, b) , since educational programs are quite costly and their effectiveness needs to be documented. Over a span of a decade, our databases now reflect cumulative changes dictated by experience. Currently, there are four interactive databases. The first (GENFO) computes sociodemographic and proband-based medical activities. GENFO can generate reports for the Council of Regional Genetics Networks and other agencies. The second database (LABFO) computes cytogenetic services and other laboratory data. A third database (FAMFO) provides rapid access to fact sheets, booklets, audiovisual materials and addresses of support groups needed by patients, families, and physicians. A fourth database is used for accounting purposes.
Using the Mobile Genetic Services Codes (Wertelecki and Superneau, 1987a) , prevalent diagnostic-genetic risk categories were derived from 1,418 consecutive service encounters (Wertelecki and Superneau, 1978b) : The following 12 clinical categories were accounted for 45 ~ of encounters (mental retardation (unclassified), neurofibromatosis, nervous system (dysplasia-malformation), Down syndrome, oro-facial malformations, Marfan syndrome, malformation syndromes, Turner syndrome, no evidence of abnormality, meningomyelocele, advanced maternal age, and rare autosomal chromosome disorders). The following 16 additional clinical categories were accounted for 17~ of additional encounters (growth failure, deafness, fetal alcohol syndrome, osteogenesis imperfecta, fragile X syndrome, trisomy 18, trisomy 13, sickle cell anemia, Klinefelter syndrome, genital malformation, microcephaly, yon Willebrand disease, Prader-Willi syndrome, hemihypertrophy, achondroplasia, and congenital heart malformatilon). Pervalent metabolic disorders encountered were albinism, phenylketonuria, mucopolysaccharidoses, galactosemia, complement deficiency, urea cycle abnormality, mucolipidoses, lactic acidosis, glycogen storage disease, adrenogenital syndrome, porphyria, Wiskott-Aldrich syndrome, hemophilia, Gaucher disease, vitiligo, Lesch-Nyhan syndrome, Wilson
